Literature DB >> 22895501

How and why AIDS changed drug policy in Switzerland.

Bertino Somaini, Peter Grob.   

Abstract

Switzerland implemented a harm reduction program and reduced the spread of HIV within the drug scene, and from drug users into other population groups, earlier than many countries. Each canton developed strategies based on its drug problem. By 1985 it was obvious that 'needle sharing' was the most significant pathway in the transmission of HIV. Some cities established Drug Consumption Rooms and small-scale syringe exchange programs. However, a dramatic concentration of drug use in the Platzspitz (a park) of Zürich evolved where 1000-2000 drug users gathered daily, many of whom were infected with HIV. The Federal Office of Public Health financed needle exchange and other harm reduction programs, with evaluation. Within a few years the Swiss established low-threshold methadone treatment programs and Heroin-Assisted Therapy. In 2008, the Swiss approved a law based on the principles of a 'four pillar system': repression, prevention, harm reduction, and treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895501     DOI: 10.1057/jphp.2012.20

Source DB:  PubMed          Journal:  J Public Health Policy        ISSN: 0197-5897            Impact factor:   2.222


  4 in total

1.  All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS).

Authors:  Maroussia Roelens; Barbara Bertisch; Darius Moradpour; Andreas Cerny; Nasser Semmo; Patrick Schmid; Beat Müllhaupt; Olivier Clerc; David Semela; Christoph Junker; Francesco Negro; Olivia Keiser
Journal:  Open Forum Infect Dis       Date:  2020-07-25       Impact factor: 3.835

2.  Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth.

Authors:  Michael Krausz; Jean N Westenberg; Vivian Tsang; Janet Suen; Martha J Ignaszewski; Nickie Mathew; Pouya Azar; Maurice Cabanis; Julie Elsner; Marc Vogel; Renske Spijkerman; Laura Orsolini; Dzung Vo; Eva Moore; Jessica Moe; Johannes Strasser; Patrick Köck; Calin Marian; Kenneth M Dürsteler; Markus Backmund; Jeanette Röhrig; Marianne Post; Hans Haltmayer; Wolfgang Wladika; Thomas Trabi; Christian Muller; Gerhard Rechberger; Maree Teesson; Michael Farrell; Grant Christie; Sally Merry; Mostafa Mamdouh; Rachel Alinsky; Sharon Levy; Marc Fishman; Richard Rosenthal; Kerry Jang; Fiona Choi
Journal:  Medicina (Kaunas)       Date:  2022-04-13       Impact factor: 2.948

Review 3.  Ethical dilemmas in protecting individual rights versus public protection in the case of infectious diseases.

Authors:  Kai-Lit Phua
Journal:  Infect Dis (Auckl)       Date:  2013-02-28

4.  The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids.

Authors:  Anna Buadze; Stephanie Baggio; Roman Schleifer; Eveline Aeberhard; Hans Wolff; Andres Schneeberger; Michael Liebrenz
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.